[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100627272":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":20,"centralContacts":21,"locations":30,"responsibleParty":49,"collaborators":20,"id":51,"slug":52,"hasResults":53,"nctId":54,"briefTitle":55,"officialTitle":56,"acronym":20,"eligibilityCriteria":57,"healthyVolunteers":53,"sex":58,"minAge":59,"maxAge":60,"enrollmentInfo":61,"targetDuration":20,"studyType":64,"phases":65,"briefSummary":67,"conditions":68,"keywords":70,"overallStatus":73,"whyStopped":20,"lastUpdateSubmitDate":74,"lastUpdatePostDateStruct":75,"startDateStruct":78,"completionDateStruct":80,"leadSponsor":82,"locationsCount":83},{"fullName":5,"class":6},"Central South University","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"TI","EXPERIMENTAL","TI group will be administered temporal interference stimulation",[13],"Device: temporal interference stimulation",[15],{"type":16,"name":17,"description":18,"armGroupLabels":19,"otherNames":20},"DEVICE","temporal interference stimulation","TIS will use 2 pairs of electrodes placed according to a 10-10 EEG system and fixed with conductive paste to produce a theta burst stimulation pattern. Electric field modeling will be performed utilizing MRI T1 images to optimize the individualized electrode configuration to generate electric field intensities above 0.4 V\u002Fm in the hippocampus of each patient. Each session of stimulation lasts 30 minutes.",[9],null,[22,27],{"name":23,"role":24,"phone":25,"phoneExt":20,"email":26},"Renrong Wu","CONTACT","15874179855","wurenrong@csu.edu.cn",{"name":28,"role":24,"phone":20,"phoneExt":20,"email":29},"Yue Qin","qinyue@csu.edu.cn",[31],{"facility":32,"status":20,"city":33,"state":34,"zip":35,"country":36,"countryCode":37,"cosmosGeoPoint":38,"geoPoint":43,"contacts":44},"Second Xiangya Hospital, Central South University","Changsha","Hunan","410011","China","CN",{"type":39,"coordinates":40},"Point",[41,42],112.97087,28.19874,{"lat":42,"lon":41},[45,47],{"name":28,"role":24,"phone":46,"phoneExt":20,"email":29},"13051119195",{"name":23,"role":48,"phone":20,"phoneExt":20,"email":20},"PRINCIPAL_INVESTIGATOR",{"type":48,"investigatorFullName":23,"investigatorTitle":50,"investigatorAffiliation":5,"oldNameTitle":20,"oldOrganization":20},"Professor","100627272","tis-for-improving-cognitive-impairment-associated-with-schizophrenia-100627272",false,"NCT07446478","TIS for Improving Cognitive Impairment Associated With Schizophrenia","Efficacy and Safety of Time Interference Stimulation on Cognitive Impairment Associated With Schizophrenia","Inclusion Criteria:\n\n* Age 18-50 years old;\n* meet the Diagnostic and Statistical Manual of Mental Disorders, Fifth edition (DSM-5) diagnostic criteria;\n* the diagnosis of schizophrenia is confirmed by the Structured Clinical Interview for DSM-5 (SCID-5);\n* the disease duration does not exceed 8 years;\n* 1-2 antipsychotic drugs are taken, and the treatment dose of antipsychotic drugs was stable for at least 1 week before enrollment. Mood stabilizers, antidepressants, and excessive benzodiazepines (lorazepam when 2 doses exceeded 2 mg\u002Fd) are not allowed;\n* The type of antipsychotic drugs remains unchanged during treatment, and the dose is adjusted by no more than 25%;\n* Impaired functioning in daily activities;\n* The Global Deficit Score (GDS) for the MATRICS Consensus Cognitive Battery (MCCB) reaches 0.5 or above;\n* Agree to participate in this study and provide written informed consent\n\nExclusion Criteria:\n\n* Presence of other psychiatric comorbidities, intellectual disability, obvious mood symptoms, or substance use disorders (other than caffeine and\u002For tobacco);\n* with clear drug-induced extrapyramidal reaction;\n* A history of seizures, meningitis, or encephalitis;\n* with contraindications to transcranial electrical stimulation;\n* History of intracranial tumors or surgery;\n* history of severe head trauma;\n* have received other regimens of electrical or magnetic therapy in 1 month before enrollment.","ALL","18 Years","50 Years",{"count":62,"type":63},10,"ESTIMATED","INTERVENTIONAL",[66],"NA","This study aims to evaluate the efficacy and safety of TIS targeting the hippocampus in ameliorating cognitive impairment associated with schizophrenia (CIAS). Participants will receive TIS twice a day for 2 weeks. Their clinical data, including the baseline clinical symptom scale score, cognitive function, and MRI data, will be collected at baseline and at the end of the 2-week intervention.",[69],"Cognitive Impairment Associated With Schizophrenia (CIAS)",[71,72,17],"schizophrenia","cognitive impairments","NOT_YET_RECRUITING","2026-03-12",{"date":76,"type":77},"2026-03-17","ACTUAL",{"date":79,"type":63},"2026-03-15",{"date":81,"type":63},"2026-05-15",{"name":5,"class":6},1]